Skip to main content
보도자료 배포 서비스
검색폼
검색
로그인
회원가입
뉴스
서비스
교육
블로그
언론 서비스
보도자료 등록
고객센터
English
MY뉴스
회사 소개
보도자료 배포 서비스
보도자료 배포 서비스
언론 서비스
보도자료 등록
고객센터
English
뉴스
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
전시회
FAQ
취소
기업 검색
로그인
회원 가입
전체
IT
건강
경제
교육
금융
라이프
레저
문화
미디어
부동산
사회
산업
유통
자동차
환경
신상품
상장기업
사진
동영상
기업 뉴스룸
Boehringer Ingelheim International GmbH
INGELHEIM, Germany
제약
http://www.boehringer-ingelheim.com
뉴스 구독하기
Boehringer Ingelheim International GmbH 뉴스
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leverag
1월 13일 09:40
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Boehringer Ingelheim announced today a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing cutting-edge use cases for quantum computing in pharmaceutical
1월 12일 11:49
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investiga
2020년 12월 21일
11:30
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug con
2020년 12월 11일
11:38
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate i
2020년 12월 10일
10:57
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic target
2020년 12월 8일
10:40
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and establis
2020년 11월 19일
13:31
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Boehringer Ingelheim today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the proposed indication for Prad
2020년 11월 16일
17:55
New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients[1]
Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
2020년 11월 6일
09:45
Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19
Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 ma
2020년 10월 29일
10:25
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic
Boehringer Ingelheim and Oxford BioTherapeutics Ltd. (OBT) today announced they are building on their successful partnership and are establishing a new alliance to discover additional selective target
2020년 10월 15일
11:49
Boehringer Ingelheim invests to further develop the pet care market in China
Boehringer Ingelheim has acquired an equity stake in China-based New Ruipeng Group (NRP Group). NRP Group is a fast-growing business that offers veterinary care, e-commerce and many other services to
2020년 9월 29일
17:46
Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint. The data showed improvement in cognition i
2020년 9월 15일
11:12
Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced they have entered into a collaboration for the development and commercialization of a prescription-based digital therapeutic. It will utiliz
2020년 9월 14일
11:11
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim today announced the advancement of the bi-specific and tetravalent therapeutic antibody, BI 905711, to its first-in-human clinical trial for patients with advanced gastrointestina
2020년 9월 11일
08:46
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart failure with reduced ejection fraction
Full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, showed that empagliflozin was associated with a significan
2020년 8월 31일
09:07
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents betwee
2020년 8월 13일
10:41
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Positive top-line results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, were announced today by Boehringer Ingelheim
2020년 7월 31일
10:09
Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health
Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and producti
2020년 7월 27일
17:33
European Commission approves third nintedanib indication in pulmonary fibrosis[1]
Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung dis
2020년 7월 16일
10:06
Perceived burden of disease is greater in younger people living with COPD, global survey reveals
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstr
2020년 7월 10일
10:27
Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
Boehringer Ingelheim and Numab Therapeutics (Numab) today announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects aiming at no
2020년 7월 8일
08:53
New consortium EUbOPEN will provide tools to unlock disease biology
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and dis
2020년 6월 9일
09:24
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis[1]
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending an additional ind
2020년 6월 1일
09:02
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining empagliflozin’s effects following an acute myocardial infarction
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin f
2020년 5월 27일
10:57
페이지당 25개
페이지당 5개
페이지당 10개
페이지당 25개
페이지당 50개
페이지당 75개
페이지당 100개
1
2
3
4
5
다음
동영상
삼성전자, 온라인 쇼케이스 통해 아웃도어TV ‘더 테라스’ 공개
언론인, 블로거 안내
MY뉴스
를 이용하면 관심있는 기업과 관심 산업 분야의 뉴스를 구독할 수 있습니다.
자세히 보기
주요 뉴스
전체 뉴스
MY뉴스
사진
동영상
상장기업
영문
기업뉴스룸
전시회
인기 토픽
RSS 구독
언론 서비스
MY뉴스 안내
보도자료 호스팅
보도자료 전송
언론인 가입
산업별 뉴스
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
물류/교통
미디어
부동산
사회
산업
스포츠
에너지/환경
유통
자동차
정책/정부
주제별 뉴스
개발
공모/모집
기업문화
기타
분양
사업계획
사회공헌
선언/의견
설립
소송
수상/선정
수주
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
주제별 뉴스
제휴
조사연구
채용
투자
판촉활동
행사
지역별 뉴스
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
서비스
왜 뉴스와이어인가?
어떻게 배포하나
산업별 미디어
지역별 미디어
해외 미디어
배포 절차와 보고서
많이 기사화된 보도자료
서비스 종류와 요금
베이직
스탠다드
프리미엄
프로페셔널
해외 홍보
부가서비스
누가 이용하나
이용 후기
고객센터
보도자료 등록
기업회원 가입
교육
홍보 마케팅 전략보고서
보도자료 작성
보도자료 유형
홍보 직무
자주하는 질문
회사 소개
블로그
연혁
파트너 되기
이용약관
편집가이드라인
사이트맵
English